# Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

> **NCT02721732** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 157 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Carcinoma of Unknown Primary
- Metastatic Adrenal Gland Pheochromocytoma
- Metastatic Kidney Medullary Carcinoma
- Metastatic Malignant Germ Cell Tumor
- Metastatic Malignant Solid Neoplasm
- Metastatic Paraganglioma
- Metastatic Penile Carcinoma
- Metastatic Skin Squamous Cell Carcinoma
- Small Cell Carcinoma
- Stage III Adrenal Cortex Carcinoma AJCC v7
- Stage IV Adrenal Cortex Carcinoma AJCC v7
- Stage IV Penile Cancer AJCC v7
- Stage IV Renal Cell Cancer AJCC v7
- Unresectable Adrenal Gland Pheochromocytoma
- Unresectable Paraganglioma
- Unresectable Skin Squamous Cell Carcinoma
- Unresectable Solid Neoplasm
- Vascular Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02721732
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-08-15
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02721732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02721732, "Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02721732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*